Allergy Therapeutics PLC 2023 AR2
The report highlights Allergy Therapeutics PLC's sustainability and financial performance for the fiscal year ended 30 June 2023. The company made progress on its ESG strategy, focusing on its four pillars: people, patients, planet, and responsible governance. Notably, the company committed to reducing Scope 1 and 2 emissions by 30% and Scope 3 by 20% by 2030, with a long-term target of a 95% reduction by 2050. Despite a challenging year with an 18% reduction in sales due to a manufacturing pause, the company continued to advance its clinical pipeline, including the Grass MATA MPL and VLP Peanut trials.
Company: Allergy Therapeutics PLC
Sector: Health Care
Country: United Kingdom
Year: 2023
Type: AR2
Pages: 128
Allergy Therapeutics PLC
Annual Report And Accounts
The report highlights Allergy Therapeutics PLC's sustainability and financial performance for the fiscal year ended 30 June 2023. The company made progress on its ESG strategy, focusing on its four pillars: people, patients, planet, and responsible governance. Notably, the company committed to reducing Scope 1 and 2 emissions by 30% and Scope 3 by 20% by 2030, with a long-term target of a 95% reduction by 2050. Despite a challenging year with an 18% reduction in sales due to a manufacturing pause, the company continued to advance its clinical pipeline, including the Grass MATA MPL and VLP Peanut trials.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jul 1, 2022 - Jun 30, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Women on Board
Net Zero Target
Employees